Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies
Author:
Publisher
Informa Healthcare
Subject
Drug Discovery
Link
http://www.tandfonline.com/doi/pdf/10.1517/17460441.2013.788496
Reference97 articles.
1. Targeting the S and G2 checkpoint to treat cancer
2. Anticancer therapy with checkpoint inhibitors: what, where and when?
3. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
4. Checkpoint kinase inhibitors: a patent review (2009 – 2010)
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights;Bioorganic Chemistry;2024-08
2. Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach;OMICS: A Journal of Integrative Biology;2024-01-01
3. Targeting the DNA Damage Response for Cancer Therapy;International Journal of Molecular Sciences;2023-11-02
4. The Discovery of Checkpoint Kinase 1 Inhibitors: From Fragments to Clinical Candidate;The Handbook of Medicinal Chemistry;2023-02-03
5. Computational design of Checkpoint Kinase-1 (CHK-1) inhibitors for cancer therapy;2023-01-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3